Clinical trial NCT05191004: Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Official title: Randomized, Non-Comparative Phase 1/2 Study of NUV-422 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (HR+HER2-) Advanced Breast Cancer (aBC)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Advanced Breast Cancer
Metastatic Breast Cancer
Breast Cancer
Breast Carcinoma
Cancer of the Breast
Cancer of Breast
Malignant Tumor of Breast
Breast Tumor
Keywords: Phase 1
Phase 2
metastatic breast cancer
advanced breast cancer
hormone receptor positive
HR+
human epidermal growth factor receptor 2 negative
HER2-
HR+ HER2-
estrogen receptor positive
ER+
NUV-422
fulvestrant
CDK
CDK inhibition
CDK2/4/6
Lead sponsor: Nuvation Bio Inc.
Sponsor class: INDUSTRY
First posted: 2022-01-13
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Sequential assignment or parallel assignment will be applied (in both Phase 1 and Phase 2), depending on the stage of the study at the time of a patient's enrollment.
Primary purpose: TREATMENT

Brief summary: NUV-422-03 is a randomized, non-comparative Phase 1/2 dose escalation and expansion study designed to evaluate the safety and efficacy of NUV-422 in combination with fulvestrant relative to NUV-422 monotherapy and fulvestrant monotherapy. The study population is comprised of adults with HR+HER2- aBC. Patients will self-administer NUV-422 orally in 28-day cycles and receive 500 mg fulvestrant intramuscularly (IM) on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.


Eligibility criteria: Inclusion Criteria:

1. Men and women with diagnosis of locally advanced inoperable or metastatic HR+HER2- breast cancer
2. Evidence of disease progression on immediate prior therapy as determined by the Investigator per standard criteria
3. Patients must have received standard of care treatments for their breast cancer and be eligible to receive fulvestrant

   * Prior standard of care treatments must include treatment with hormonal therapy in combination with an approved CDK4/6 inhibitor
4. Patients must have endocrine-resistant disease
5. Have no known active or symptomatic central nervous system (CNS) disease
6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1
7. Life expectancy of \> 6 months
8. Eligible to receive fulvestrant
9. Adequate bone marrow and organ function

Exclusion Criteria:

1. Have received chemotherapy, hormonal therapy (with the exception of ongoing LHRH analogs in male patients and premenopausal women), radiation, or biological anti-cancer therapy within 14 days prior to the first dose of NUV-422 and fulvestrant
2. Received treatment with an investigational agent for any indication within 14 days for non-myelosuppressive agent or 21 days (of \< 5 half-lives) for myelosuppressive agent prior to first dose of NUV-422 and fulvestrant
3. Moderate liver impairment which would require a reduced dose of fulvestrant
4. Requires medications that are known to be strong inducers and/or inhibitors of CYP3A4/5 enzymes

   * For Phase 1b only: requires medications that are known to be moderate inducers and/or inhibitors of CYP3A4/5 enzymes
5. Known allergy or hypersensitivity to fulvestrant
6. For Phase 2 only: prior therapy with fulvestrant and/or investigational ER targeted agent
7. Females who are pregnant or breast feeding

Primary outcomes:
measure: Phase 1b Dose Escalation: Safety and tolerability of NUV-422 in combination with fulvestrant to determine the recommended Phase 2 combination dose (RP2cD)
timeFrame: During the DLT period (28 days)
measure: Phase 2 Dose Expansion: Objective Response Rate (ORR)
timeFrame: Every 8 weeks through study treatment, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Anaheim
country: United States
facility: Pacific Cancer Medical Center, Inc.
state: California
city: Fountain Valley
country: United States
facility: Compassionate Cancer Care Research Inc.
state: California
city: Canton
country: United States
facility: Gabrail Cancer Center Research
state: Ohio
city: Gettysburg
country: United States
facility: Pennsylvania Cancer Specialists and Research Institute
state: Pennsylvania
city: Fairfax
country: United States
facility: NEXT Virginia
state: Virginia
Study officials:
References: